The FDA rejected ivonescimab, a PD-1/VEGF therapy being developed by Summit Therapeutics and Akeso. Regulators concluded the drug could not be approved because it did not improve overall survival in the studied setting, despite evidence of slowing disease progression. The decision represents a setback for Summit’s development plans outside China and follows a broader period of heightened scrutiny for oncology approvals where survival endpoints are required to support benefit-risk profiles. The rejection narrows the path for PD-1/VEGF strategies in the specific niche where ivonescimab was evaluated. Analysts said the outcome was not entirely unexpected given the survival signal, but it still removes a high-profile program from the approval pipeline.
Get the Daily Brief